Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Onvatilimab (CI-8993) in Advanced Solid Tumors
NCT04475523Phase 1Completed
- Sponsor
- Curis, Inc.
- Start
- Sep 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of onvatilimab in solid tumor, sponsored by Curis, Inc. Primary endpoints: Maximum Tolerated Dose at 2 years and Recommended Phase 2 Dose at 2 years. Started Sep 2020; status: completed.
02
Drugs
onvatilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04475523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475523.